CRUCELL-ADR (CRXL) - Profit Tracks

Since inception in 1988, the S&P 500 has outperformed the Zacks #5 Rank List - Stocks to Sell Now by 80% annually (+2% versus +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why TRLG and CRXL have a Zacks Rank of #5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

True Religion Apparel, Inc. (TRLG< /a>)reported third quarter earnings of 48 cents per share on November 3, which came in 10 cents behind analyst?s expectations. The Zacks Consensus Estimate for the current year decreased 22 cents to $1.85 over the past month as all the 5 covering analysts cut back on projections. During that period next year?s forecast fell 31 cents to $2.10 per share.

Crucell N.V. (ADR) (CRXL< /a>)announced third - quarter loss per share of 43 cents on November 9, which fell short of the Zacks Consensus Estimate by 61%. The Zacks Consensus Estimate for 2010 slipped 32 cents to a loss of 47 cents per share in the last week, which reflected reductions by all the 4 covering analysts. Next year?s estimate fell 8 cents to 69 cents per share in the same period.

Here is a synopsis of why LIZ and DGX have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;

Liz Claiborne, Inc. (LIZ)On November 4 Liz Claiborne, Inc. reported a loss of 24 cents per share, which lagged the Zacks Consensus Estimate by nearly 22%. The Zacks Consensus Estimate for the present year fell 20 cents to a loss of 66 cents per share in the past 30 days as 6 out of the 7 covering analysts reduced forecasts.

Quest Diagnostics Inc.?s (DGX)first-quarter earnings of 41 cents per share, reported on October 28, missed analysts? projections by nearly 13%. The Zacks Consensus Estimate for 2010 slid 12 cents to $1.90 per share in the last 30 days as all the 14 covering analysts revised downward. The average forecast for the following year declined 14 cents to $2.18 per share in that time span.
 
AVON PRODS INC (AVP): Free Stock Analysis Report
 
CRUCELL-ADR (CRXL): Free Stock Analysis Report
 
LIZ CLAIBORNE (LIZ): Free Stock Analysis Report
 
TRUE RELIGION (TRLG): Free Stock Analysis Report
 
Zacks Investment Research